GSK Handling Of Paxil Data On Pediatric Use Is Subject Of N.Y. Lawsuit
This article was originally published in The Pink Sheet Daily
Executive Summary
The state attorney general alleges that GSK failed to publish information about the safety and efficacy of Paxil in children. The lawsuit seeks disgorgement of profits. GSK maintains that it has publicly communicated the data from its pediatric studies.
You may also be interested in...
FDA ClinicalTrials.gov Report Will Show Growing Rate Of Study Listings
The forthcoming report also will show increased disclosure of company sponsors and drug names in trial descriptions. FDA has added language to IND acknowledgement letters to promote compliance with listing requirements.
FDA ClinicalTrials.gov Report Will Show Growing Rate Of Study Listings
The forthcoming report also will show increased disclosure of company sponsors and drug names in trial descriptions. FDA has added language to IND acknowledgement letters to promote compliance with listing requirements.
GSK Settles With N.Y.; Company Will Post Past Trial Data By End Of 2005
The settlement includes a modest $2.5 mil. disgorgement fee. GSK is also required to advertise the clinical trial register in seven prominent peer reviewed journals.